Literature DB >> 26297272

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Michael Y Choi1, George F Widhopf1, Christina C N Wu1, Bing Cui1, Fitzgerald Lao1, Anil Sadarangani2, Joy Cavagnaro3, Charles Prussak1, Dennis A Carson1, Catriona Jamieson2, Thomas J Kipps4.   

Abstract

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT; CLL; Cirmtuzumab; Wnt receptor; cancer stem cell

Mesh：

Substances：

Year:  2015        PMID： 26297272      PMCID： PMC4548279          DOI： 10.1016/j.clml.2015.02.010

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


  24 in total

1.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

2.  The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.

Authors:  Alessandra Gentile; Luca Lazzari; Silvia Benvenuti; Livio Trusolino; Paolo Maria Comoglio
Journal:  Int J Cancer       Date:  2014-04-15       Impact factor: 7.396

Review 3.  Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

Authors:  Tadeusz Robak
Journal:  Expert Rev Hematol       Date:  2014-09-24       Impact factor: 2.929

4.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Authors:  Carolina Berger; Daniel Sommermeyer; Michael Hudecek; Michael Berger; Ashwini Balakrishnan; Paulina J Paszkiewicz; Paula L Kosasih; Christoph Rader; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-10-29       Impact factor: 11.151

5.  Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.

Authors:  Suping Zhang; Bing Cui; Hsien Lai; Grace Liu; Emanuela M Ghia; George F Widhopf; Zhuhong Zhang; Christina C N Wu; Liguang Chen; Rongrong Wu; Richard Schwab; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-19       Impact factor: 11.205

6.  The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.

Authors:  Suping Zhang; Liguang Chen; Jessica Wang-Rodriguez; Ling Zhang; Bing Cui; Wendy Frankel; Rongrong Wu; Thomas J Kipps
Journal:  Am J Pathol       Date:  2012-10-04       Impact factor: 4.307

7.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

8.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

9.  Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.

Authors:  R Mani; Y Mao; F W Frissora; C-L Chiang; J Wang; Y Zhao; Y Wu; B Yu; R Yan; X Mo; L Yu; J Flynn; J Jones; L Andritsos; S Baskar; C Rader; M A Phelps; C-S Chen; R J Lee; J C Byrd; L J Lee; N Muthusamy
Journal:  Leukemia       Date:  2014-06-20       Impact factor: 11.528

10.  ROR1 expression correlated with poor clinical outcome in human ovarian cancer.

Authors:  Huilin Zhang; Jinrong Qiu; Chunping Ye; Dazhen Yang; Lingjuan Gao; Yiping Su; Xiaojun Tang; Ning Xu; Dawei Zhang; Lin Xiong; Yuan Mao; Fengshan Li; Jin Zhu
Journal:  Sci Rep       Date:  2014-07-24       Impact factor: 4.379
View more
  48 in total

Review 1.  The Wnt signaling pathway in cancer.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-24       Impact factor: 6.312

Review 2.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

3.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

4.  Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.

Authors:  Shivani Srivastava; Alexander I Salter; Denny Liggitt; Sushma Yechan-Gunja; Megha Sarvothama; Kirsten Cooper; Kimberly S Smythe; Jarrod A Dudakov; Robert H Pierce; Christoph Rader; Stanley R Riddell
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

5.  Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia.

Authors:  Francesca Lovat; Giovanni Nigita; Rosario Distefano; Tatsuya Nakamura; Pierluigi Gasparini; Luisa Tomasello; Paolo Fadda; Narmin Ibrahimova; Silvia Catricalà; Alexey Palamarchuk; Michael A Caligiuri; Anna Gallì; Luca Malcovati; Mark D Minden; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-18       Impact factor: 11.205

Review 6.  Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Methods Mol Biol       Date:  2017

7.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Authors:  Ashwini Balakrishnan; Tracy Goodpaster; Julie Randolph-Habecker; Benjamin G Hoffstrom; Florencia G Jalikis; Lisa K Koch; Carolina Berger; Paula L Kosasih; Anusha Rajan; Daniel Sommermeyer; Peggy L Porter; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

8.  Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Authors:  Hanna Karvonen; David Chiron; Wilhelmiina Niininen; Sara Ek; Mats Jerkeman; Elaheh Moradi; Matti Nykter; Caroline A Heckman; Olli Kallioniemi; Astrid Murumägi; Daniela Ungureanu
Journal:  Blood Adv       Date:  2017-11-09

Review 9.  MicroRNA dysregulation and multi-targeted therapy for cancer treatment.

Authors:  Veronica Balatti; Carlo M Croce
Journal:  Adv Biol Regul       Date:  2019-10-13

10.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.